Phase I first-in-human dose escalation study of the oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 in advanced MDS and AML.
口服酪蛋白激酶 1α 和细胞周期蛋白依赖性激酶 7/9 抑制剂 BTX A51 在晚期 MDS 和 AML 中的 I 期首次人体剂量递增研究
期刊:Journal of Hematology & Oncology
影响因子:40.4
doi:10.1186/s13045-025-01724-z
Ball Brian J, Xiao Wenbin, Borthakur Gautam, Nguyen Le Xuan Truong, Valerio Melissa, Venkatachalam Avanthika, Marcucci Guido, Stein Anthony S, Thai Dung Luong, Cook David N, Chan Kyle, Persaud Sonali, Levine Ross L, Abdel-Wahab Omar, Ben-Neriah Yinon, Stein Eytan M